Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 163952 | 3.592 |
09:34 ET | 30154 | 3.59 |
09:36 ET | 77366 | 3.57 |
09:38 ET | 18668 | 3.595 |
09:39 ET | 20965 | 3.59 |
09:41 ET | 21015 | 3.595 |
09:43 ET | 27059 | 3.615 |
09:45 ET | 34097 | 3.635 |
09:48 ET | 24901 | 3.655 |
09:50 ET | 24812 | 3.65 |
09:52 ET | 52364 | 3.675 |
09:54 ET | 27344 | 3.66 |
09:56 ET | 50456 | 3.68 |
09:57 ET | 69271 | 3.685 |
09:59 ET | 84940 | 3.6994 |
10:01 ET | 137032 | 3.695 |
10:03 ET | 277914 | 3.695 |
10:06 ET | 62035 | 3.71 |
10:08 ET | 7220 | 3.705 |
10:10 ET | 49640 | 3.72 |
10:12 ET | 66672 | 3.745 |
10:14 ET | 71223 | 3.78 |
10:15 ET | 117946 | 3.7801 |
10:17 ET | 27730 | 3.79 |
10:19 ET | 23800 | 3.785 |
10:21 ET | 106282 | 3.795 |
10:24 ET | 2476 | 3.795 |
10:26 ET | 171190 | 3.79 |
10:28 ET | 101667 | 3.805 |
10:30 ET | 7609 | 3.81 |
10:32 ET | 18276 | 3.815 |
10:33 ET | 116008 | 3.805 |
10:35 ET | 43256 | 3.795 |
10:37 ET | 39276 | 3.82 |
10:39 ET | 82175 | 3.785 |
10:42 ET | 16323 | 3.7905 |
10:44 ET | 11282 | 3.7813 |
10:46 ET | 48974 | 3.76 |
10:48 ET | 34971 | 3.7799 |
10:50 ET | 3550 | 3.775 |
10:51 ET | 12234 | 3.765 |
10:53 ET | 157665 | 3.755 |
10:55 ET | 28933 | 3.7594 |
10:57 ET | 200 | 3.76 |
11:00 ET | 16373 | 3.765 |
11:02 ET | 12438 | 3.77 |
11:04 ET | 8300 | 3.7688 |
11:06 ET | 76126 | 3.7625 |
11:08 ET | 96564 | 3.765 |
11:09 ET | 4695 | 3.7601 |
11:11 ET | 31162 | 3.755 |
11:13 ET | 1183 | 3.76 |
11:15 ET | 15580 | 3.76 |
11:18 ET | 13185 | 3.765 |
11:20 ET | 2100 | 3.765 |
11:22 ET | 10068 | 3.755 |
11:24 ET | 13656 | 3.7699 |
11:26 ET | 3910 | 3.7652 |
11:27 ET | 1313 | 3.765 |
11:29 ET | 30882 | 3.765 |
11:31 ET | 22229 | 3.76 |
11:33 ET | 30398 | 3.755 |
11:36 ET | 139821 | 3.77 |
11:38 ET | 27148 | 3.78 |
11:40 ET | 6840 | 3.785 |
11:42 ET | 52723 | 3.77 |
11:44 ET | 25852 | 3.76 |
11:45 ET | 6500 | 3.76 |
11:47 ET | 12009 | 3.765 |
11:51 ET | 600 | 3.76 |
11:54 ET | 8178 | 3.76 |
11:56 ET | 66373 | 3.75 |
11:58 ET | 12867 | 3.755 |
12:00 ET | 90603 | 3.7594 |
12:02 ET | 13970 | 3.76 |
12:03 ET | 7568 | 3.76 |
12:05 ET | 65007 | 3.775 |
12:07 ET | 7756 | 3.78 |
12:09 ET | 13814 | 3.79 |
12:12 ET | 5307 | 3.79 |
12:14 ET | 18925 | 3.795 |
12:16 ET | 2300 | 3.8 |
12:18 ET | 7798 | 3.795 |
12:20 ET | 2336 | 3.8 |
12:21 ET | 2400 | 3.795 |
12:23 ET | 27692 | 3.785 |
12:25 ET | 7999 | 3.79 |
12:27 ET | 2337 | 3.785 |
12:30 ET | 17002 | 3.775 |
12:32 ET | 37226 | 3.775 |
12:34 ET | 2454 | 3.78 |
12:36 ET | 25500 | 3.78 |
12:38 ET | 2300 | 3.785 |
12:39 ET | 6262 | 3.7778 |
12:41 ET | 10930 | 3.79 |
12:43 ET | 11530 | 3.78 |
12:45 ET | 22373 | 3.775 |
12:48 ET | 6017 | 3.7729 |
12:50 ET | 100 | 3.77 |
12:52 ET | 200 | 3.77 |
12:54 ET | 1324 | 3.77 |
12:56 ET | 914 | 3.775 |
12:57 ET | 15757 | 3.785 |
12:59 ET | 6663 | 3.785 |
01:01 ET | 16790 | 3.795 |
01:03 ET | 8200 | 3.795 |
01:06 ET | 26150 | 3.805 |
01:08 ET | 33207 | 3.785 |
01:10 ET | 3974 | 3.785 |
01:12 ET | 17799 | 3.795 |
01:14 ET | 8100 | 3.7902 |
01:15 ET | 2970 | 3.8 |
01:17 ET | 10074 | 3.795 |
01:19 ET | 58198 | 3.775 |
01:21 ET | 5831 | 3.775 |
01:24 ET | 9118 | 3.78 |
01:26 ET | 60382 | 3.7821 |
01:28 ET | 9670 | 3.78 |
01:30 ET | 1300 | 3.785 |
01:32 ET | 22187 | 3.785 |
01:33 ET | 2500 | 3.785 |
01:35 ET | 9797 | 3.7895 |
01:37 ET | 1800 | 3.785 |
01:39 ET | 2300 | 3.785 |
01:42 ET | 14734 | 3.8 |
01:44 ET | 1850 | 3.8 |
01:46 ET | 38271 | 3.81 |
01:48 ET | 35665 | 3.82 |
01:50 ET | 2600 | 3.82 |
01:51 ET | 73331 | 3.825 |
01:53 ET | 5948 | 3.83 |
01:55 ET | 54962 | 3.805 |
01:57 ET | 3100 | 3.81 |
02:00 ET | 6324 | 3.805 |
02:02 ET | 5370 | 3.805 |
02:04 ET | 102272 | 3.795 |
02:06 ET | 829 | 3.795 |
02:08 ET | 1820 | 3.795 |
02:09 ET | 6866 | 3.795 |
02:11 ET | 1928 | 3.795 |
02:13 ET | 4200 | 3.795 |
02:15 ET | 18505 | 3.795 |
02:18 ET | 17267 | 3.795 |
02:20 ET | 8731 | 3.8 |
02:22 ET | 10676 | 3.795 |
02:24 ET | 1667 | 3.8 |
02:26 ET | 5041 | 3.8 |
02:27 ET | 19779 | 3.81 |
02:29 ET | 6617 | 3.8001 |
02:31 ET | 6372 | 3.805 |
02:33 ET | 20799 | 3.795 |
02:36 ET | 11165 | 3.795 |
02:38 ET | 32426 | 3.812 |
02:40 ET | 20804 | 3.8078 |
02:42 ET | 2952 | 3.81 |
02:44 ET | 19710 | 3.815 |
02:45 ET | 7709 | 3.815 |
02:47 ET | 1700 | 3.815 |
02:49 ET | 2147 | 3.815 |
02:51 ET | 3525 | 3.815 |
02:54 ET | 223442 | 3.8294 |
02:56 ET | 59390 | 3.825 |
02:58 ET | 57552 | 3.825 |
03:00 ET | 3420 | 3.82 |
03:02 ET | 5774 | 3.83 |
03:03 ET | 30757 | 3.815 |
03:05 ET | 15615 | 3.815 |
03:07 ET | 2463 | 3.82 |
03:09 ET | 12762 | 3.83 |
03:12 ET | 6075 | 3.825 |
03:14 ET | 5235 | 3.825 |
03:16 ET | 6026 | 3.82 |
03:18 ET | 25422 | 3.815 |
03:20 ET | 3270 | 3.81 |
03:21 ET | 23266 | 3.8 |
03:23 ET | 8375 | 3.805 |
03:25 ET | 19274 | 3.815 |
03:27 ET | 48649 | 3.815 |
03:30 ET | 3940 | 3.815 |
03:32 ET | 39777 | 3.81 |
03:34 ET | 20296 | 3.8 |
03:36 ET | 19749 | 3.7931 |
03:38 ET | 4755 | 3.795 |
03:39 ET | 7435 | 3.79 |
03:41 ET | 167486 | 3.79 |
03:43 ET | 19251 | 3.795 |
03:45 ET | 13410 | 3.795 |
03:48 ET | 50608 | 3.79 |
03:50 ET | 36239 | 3.79 |
03:52 ET | 75163 | 3.795 |
03:54 ET | 61091 | 3.79 |
03:56 ET | 125994 | 3.81 |
03:57 ET | 176977 | 3.785 |
03:59 ET | 1285974 | 3.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -11.7x | --- |
Vera Therapeutics Inc | 2.2B | -17.4x | --- |
Dyne Therapeutics Inc | 2.1B | -6.3x | --- |
Keros Therapeutics Inc | 2.1B | -11.1x | --- |
Avidity Biosciences Inc | 2.3B | -8.4x | --- |
Celldex Therapeutics Inc | 2.3B | -12.5x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $237.0K |
Shares Outstanding | 586.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-0.32 |
Book Value | $0.46 |
P/E Ratio | -11.7x |
Price/Sales (TTM) | 9,385.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -81,832.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.